13 completed, 2 terminated, 1 approved for marketing. 10 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Terminated 2 |
| Phase 1 | 7 | Completed 6, Terminated 1 |
Follow MorphoSys AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| MOR202 for Refractory MN MOR202 - Membranous Nephropathy | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2021-10-22 | 2026-07-13 |
| Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL Diffuse Large B Cell Lymphoma | Completed | MorphoSys AG | 3573 | 2020-04-01 | 2021-10-20 | |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL Tafasitamab, Tafasitamab plus lenalidomide - Diffuse Large B-cell Lymphoma | Phase 1 | Completed | MorphoSys AG | 66 | 2019-12-11 | 2024-10-16 |
| Lenalidomide Monotherapy in R/R DLBCL Diffuse Large B Cell Lymphoma | Completed | MorphoSys AG | 490 | 2019-04-12 | 2022-08-24 | |
| Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343) - Neoplasms | Phase 1 | Completed | Bayer | 173 | 2017-05-26 | 2022-06-30 |
| Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi Tafasitamab, Idelalisib, Venetoclax - Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia | Phase 2 | Completed | MorphoSys AG | 24 | 2016-11-01 | 2021-12-20 |
| First in Human of Single and Multiple Doses of MOR106 MOR106 single ascending doses, intravenous, Placebo single ascending doses, intravenous, MOR106 multiple ascending doses, intravenous - Healthy, Dermatitis, Atopic | Phase 1 | Completed | Lakefront Biotherapeutics NV | 81 | 2016-04-01 | 2017-10-05 |
| Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Tafasitamab, Lenalidomide - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | MorphoSys AG | 81 | 2016-03-29 | 2023-10-23 |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL MOR00208, lenalidomide, Correlative Studies - Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 41 | 2014-01-17 | 2025-12-15 |
| Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) MOR00208 (formerly Xmab 5574) - Non-Hodgkin Lymphoma | Phase 2 | Completed | MorphoSys AG | 92 | 2013-04-23 | 2023-11-07 |
| Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) MOR00208 (formerly Xmab5574) - Acute Lymphoblastic Leukemia | Phase 2 | Terminated | MorphoSys AG | 22 | 2013-04-01 | 2018-02-22 |
| Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis MOR103, Placebo - Multiple Sclerosis | Phase 1 / Phase 2 | Completed | MorphoSys AG | 32 | 2012-01-01 | 2014-11-21 |
| A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma MOR03087 phase 1 dose escalation, MOR03087, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | MorphoSys AG | 91 | 2011-07-01 | 2021-11-16 |
| Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis MOR103 - Rheumatoid Arthritis | Phase 1 / Phase 2 | Completed | MorphoSys AG | 96 | 2009-12-01 | 2014-10-24 |
| Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression - DLBCL | Approved for marketing | MorphoSys AG | 2020-08-28 |
Lymphoma, Large B-Cell, Diffuse (6) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Arthritis, Rheumatoid (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Dermatitis, Atopic (1) · Glomerulonephritis, Membranous (1) · Leukemia, Prolymphocytic (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Multiple Sclerosis (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
tafasitamab (8) · Lenalidomide (5) · Otilimab (2) · felzartamab (2) · Cisplatin (1) · Dexamethasone (1) · Gemcitabine (1) · anetumab ravtansine (1) · idelalisib (1) · pomalidomide (1) · venetoclax (1)
United States (10) · Germany (8) · Italy (8) · Spain (6) · Belgium (5) · France (5) · Poland (5) · United Kingdom (5) · Austria (4) · Hungary (3) · South Korea (3) · Australia (2) · Canada (2) · Czechia (2) · Netherlands (2)
Roman P Korolkiewicz, MD, PhD (2) · Anke Muth (1) · Elias Jabbour, MD (1) · Eva Waltl (1) · Giuseppe Remuzzi, MD (1) · Helen Timmis, MBChB (1) · Jennifer Woyach, MD (1) · Johannes Duell, MD (1) · Rebecca Klisovic, MD (1) · Wing H. Leung, M.D., PhD (1)
PMID 35674661, PMID 24534756, PMID 29444231, PMID 32171061, PMID 32511983, PMID 34196165, PMID 34343354, PMID 34414843, PMID 34433649, PMID 34779360, PMID 35861632, PMID 37171597, PMID 37369099, PMID 37646664, PMID 40802906, PMID 42027554
2014 (1), 2016 (1)